AAV Serotype Screening Platform

Overview

With its proprietary π-Icosa High-capacity and High-precision AAV serotype screening platform PackGene aims to identify tissue-specific and maximally infective AAV serotypes for clinical trial development. High infectivity and tissue specificity can ultimately reduce the dosage and production cost of AAV-based gene therapies while simultaneously increasing safety and efficacy.

Advantages

icon-6

Capacity

Our platform design results in higher library capacity

icon-3

Precision

Higher precision AAV-serotype screening

icon-11

Efficacy

High infectivity and tissue specificity can result in reduced dosage requirements that increase both safety and efficacy.

Intellectual Property

PackGene has three patents pending.

tissue targeting aav
  • Library>1 billion mutants
  • Screens AAVs for tissue specificity.

Contact Us

2. Contact us (page)